Dr Reddy S Laboratories Limited (RDY) Return on Assets ROA from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Dr Reddy s Laboratories Limited  (NYSE: RDY)


Dr Reddy S Laboratories Limited's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Dr Reddy S Laboratories Limited's ROA in the fourth quarter of 2026?
Dr Reddy s Laboratories Limited achieved a return on average assets (ROA) of 6.89 % in its fourth quarter of 2026, which is below Dr Reddy S Laboratories Limited's average return on assets, which stands at 9.83%.

ROA fell compared to the third quarter of 2026, despite the net income growth of % from the third quarter of 2026.

However, within the Healthcare sector 124 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2026 from to 859.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Mar 31 2025)
IV. Quarter
Y / Y Total Assets Change 6.98 % 32.39 % 6.98 % -35.79 % 24.13 %
Y / Y Net Income Change -32.64 % - - - 0.45 %
Net Income (TTM) in million 452 671 671 671 671
Return On Assets (TTM) 6.89 % 10.38 % 11.2 % 11.39 % 9.94 %
RDY's Total Ranking # 859 # # # # 500
Total Assets (TTM) in million 6,175 7,726 6,175 6,175 5,772
Seq. Total Assets Change -20.08 % 25.12 % 0 % 6.98 % -1.1 %
Seq. Net Income Change - - - - -

RDY's 5 Years Annual ROA >> Back to RDY Management Effectiveness >> Compare RDY ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 47
Sector # 125
Overall # 853

Return On Assets Statistics
High Average Low
14.37 %
9.83 %
6.5 %
(Mar 31 2024)   (Mar 31 2021)





Financial Statements
Dr Reddy S Laboratories Limited's Assets $ 6,175 million RDY's Balance sheet
Dr Reddy S Laboratories Limited's Income $ 452 million Quarterly RDY's Income Statement
RDY's Income by Division See RDY's Income by Division



Annual Return On Assets (Mar 31 2026)
FY 2026		 (Mar 31 2025)
FY 2025		 (Mar 31 2024)
FY 2024		 (Mar 31 2023)
FY 2023		 (Mar 31 2022)
FY 2022
Y / Y Total Assets Change -35.79 % 27.16 % 30.66 % 12.61 % 6.58 %
Total Assets in million 6,175 9,616 7,562 5,788 5,140
Y / Y Net Income Change -32.64 % 0.45 % 21.9 % 76.21 % 31.78 %
Net Income in million 452 671 668 548 311
Annual Return On Assets 7.32 % 6.98 % 8.83 % 9.47 % 6.05 %

RDY's 5 Years Annual ROA >> Back to RDY Management Effectiveness >> Compare RDY ROA to its Competitors



Comment on RDY's ROA in the fiscal year ending 2026
Despite deterioration in net income of -32.64 % to $452.00 million, Dr Reddy S Laboratories Limited's ROA improved in the fiscal year2026 to 7.32 % compared to previous year, as the value of RDY's assets decline even faster to $6,175.00 million, from $6,175.00 a year before.


More Return On Assets Ratios
RDY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RDY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RDY's Competitors
Subscribers only: Roa for Dr Reddy S Laboratories Limited's Suppliers
Subscribers only: Return On Assets for RDY's Customers

You may also want to know
RDY's Roi RDY's Inventory Turnover Ratio RDY's Growth Rates RDY's Dividend Comparisons
RDY's Profitability Ratios RDY's Asset Turnover Ratio RDY's Dividend Growth
RDY's Roe RDY's Valuation Ratios RDY's Financial Strength Ratios RDY's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA
Pro dex Inc   18.35 %
Electromed Inc   18.31 %
Soleno Therapeutics Inc  18.25 %
Resmed Inc   18.18 %
Protalix Biotherapeutics inc   17.75 %
Krystal Biotech Inc   17.62 %
Zoetis Inc   17.60 %
United Therapeutics Corporation  17.25 %
Vertex Pharmaceuticals Inc  17.18 %
Chemed Corporation  16.20 %
Gilead Sciences Inc   16.06 %
Transmedics Group Inc   15.85 %
Inspire Medical Systems inc   15.30 %
Neurocrine Biosciences Inc   15.12 %
Strata Critical Medical Inc   15.09 %
Intuitive Surgical Inc   14.98 %
Halozyme Therapeutics Inc   14.73 %
Profound Medical Corp   13.91 %
Aveanna Healthcare Holdings Inc   13.73 %
Standard Biotools Inc   13.58 %
Illumina Inc   13.40 %
Dexcom Inc   13.39 %
West Pharmaceutical Services Inc   13.21 %
Apellis Pharmaceuticals Inc   13.20 %
Prestige Consumer Healthcare Inc   13.01 %
Hca Healthcare Inc   12.94 %
Lantheus Holdings Inc   12.45 %
Puma Biotechnology Inc   12.09 %
Harmony Biosciences Holdings inc   11.99 %
Carlisle Companies Incorporated  11.97 %

Date modified: 2026-07-07T13:23:39+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.